hyperopia, you are so correct about timeline estimates. The hurdles along this one have been most difficult to foresee. I once bet a former colleague and close friend a cheesesteak that NWBO's trial would be voluntarily reviewed by FDA by 2018 and there would be a regulatory pathway identified for rapid approval given patient clinical gains in such a lethal therapeutic space with a highly benign safety profile.
Needless to say I bought that cheesesteak and kept a long running annual bet that NWBO would get approved for GBM and much more, good thing I enjoy cheesesteaks.
There is a reason, as you know, for this. When all is said and done it will be, on one level unfortunate for immediate patients who could not attain DCVax-L for their GBM, but on another level it will be a marvelous achievement for many current and all future patients.
On about every level of product development, clinical development, medical science development, regulatory pathway and financial management this will be an amazing feat by an ultra tiny entity, for better or worse, which is not typically how such major breakthroughs which have had to follow newly cut paths, are accomplished.
Shareholders patience, support, credibility and betting persistence has been tested but will be rewarded in the end.
GLTA
News 
Market Data 
Discover 
